References

Table A

 

w1	Frei M, Küster L, von Krosigk PG, Koch H, Küppers. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994;24(Suppl 1):S25-S28
w2	Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990;263:1507-12
w3	Petersen JR, Drabaek H, Gleerup G, Mehlsen J, Petersen LJ, Winther K. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension. Angiology 1996;47:233-40
w4	Scholze J, Breitstadt A, Cairns V, Bauer B, Bender N, Priestley, et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993;11:217-21
w5	Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990;39:327-32
w6	Muiesan G, Agabiti-Rosei E, Buoninconti R, Cagli V, Carotti A, Corea L, et al. Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study. J Hypertens 1987;5 (Suppl 5):S599-S602
w7	Kayanakis JG, Baulac L. Comparative study of once-daily administration of captopril 50mg, hydrochlorothiazide 25mg and their combination in mild to moderate hypertension. Br J Clin Pharmacol 1987;23 (Suppl 1):89S-92S
w8	Wing LMH, Arnolda LF, Harvey PJ, Upton J, Molloy D, Bune AJC, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. J Hypertens 1997;15:1503-10
w9	MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 1996;156:278-85
w10	Chalmers JP, Morris MJ, Wing LMH, Cain MD, West MJ, Graham JR, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust NZ J Med 1986;16:475-80
w11	Chalmers JP, Korner PI, Tiller DJ, Bune AJ, Steiner JD, West MJ, et al. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. Med J Aust 1976;1:650-3
w12	Chalmers J, Horvath J, Tiller D, Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Lancet 1976;2:328-31
w13	McCorvey E, Wright JT, Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clinical Pharmacy 1993;12:300-5
w14	Myers MG, de Champlain J. Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. Hypertension 1983;5:591-6
w15	Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, an new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol 1996;50:259-64
w16	Pool J, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens 1997;10:117-23
w17	Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. Clin Ther 1993;15:779-87
w18	Moser M, Abraham PA, Bennett WM, Brachfeld N, Goodman RP, McKenney JM, et al. The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. Clin Pharmacol Ther 1991;49:322-9
w19	Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Human Hypertens 1998;12:861-6
w20	Canter D, Frank GJ, Knapp LE, Phelps M, Quade M, Texter M. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens 1994;8:155-62
w21	Fernández M, Madero R, González D, Camacho P, Villalpando J, Arriaga J. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension 1994;23 (Suppl I):I-207-10
w22	Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994;8:283-8
w23	Pordy RC. Cilazapril plus hydrochlorothiazide: improved efficacy without reduced safety in mild to moderate hypertension. Cardiology 1994;85:311-22
24	Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992;6:133-8
w25	Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35:182-8
w26	Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 1996;5:17-24
w27	Goldberg MR, Rockhold FW, Offen WW, Dornseif BE. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther 1989;46:208-18
w28	Pool PE, Applegate WB, Woehler T, Sandall P, Cady WJ. A randomized, controlled trial comparing diltiazem, hydrochlorothiazide, and their combination in the therapy of essential hypertension. Pharmacotherapy 1993;13:487-93
w29	Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-9
w30	Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12:797-805
w31	Jueng C, Halperin AK, Hasmimoto F, Callender K. Nifedipine GITS and hydrochlorothiazide in essential hypertension. J Clin Hypertens 1987;3:695-703
w32	Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 1982;128:903-7
w33	Jounela AJ, Lilja M, Lumme J, Mörlin C, Hoyem A, Wessel-aas T, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994;3:231-5
w34	Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med 1994;154:737-43
w35	Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther 1978;24:192-8
w36	Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. b Blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. BMJ 1984;289:406-9
w37	Salvetti A, Magagna A, Innocenti P, Ponzanelli F, Cagianelli A, Cipriani M, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. J Cardiovasc Pharmacol 1991;17:332-5
w38	Wing LMH, West MJ, Graham JR, Chalmers JP. Long-acting and short-acting diuretics in mild essential hypertension. Clin Exp Hypertens 1982;A4:1429-41
w39	Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol 1979;7:357-63
w40	Morledge JH, Ettinger B, Aranda J, BcBarron F, Barra P, Gorwit J, et al. Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. J Am Geriatr Soc 1986;34:199-206
w41	Cranston WI, Juel-Jensen BE. The effects of spironolactone and chlorthalidone on arterial pressure. Lancet 1962;1:1161-4
w42	Ferrara LA, de Simone G, Mancini M, Fasano ML, Pasanisi F, Vallone G. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. Eur J Clin Pharmacol 1984;27:525-8
w43	Durel LA, Hayashi PJ, Weidler DJ, Schneiderman N. Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. J Clin Pharmacol 1992;32:564-70
w44	Bradley K, Flack JM, Belcher J, Elmer P, Miller P, Grimm R. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. Am J Hypertens 1993;6:636-9
w45	Moser M. Low-dose diuretic therapy for hypertension. Clin Ther 1986;8:554-62
w46	McFate Smith WM, Feigal DW, Furberg CD, Greenlick M, Kuller L, Perry HM, et al. Use of diuretics in treatment of hypertension in the elderly. Drugs 1986;31:154-64
w47	Hall WD, Weber MA, Ferdinand K, Flamenbaum W, Marbury T, Jain AK, et al. Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. J Hum Hypertens 1994;8:571-5
w48	Schaller M, Waeber B, Brunner HR. Double-blind comparison of indapamide with a placebo in hypertensive patients treated by practicing physicians. Clin Exp Hypertens 1985;A7:985-94
w49	Fiddes R, Blumenthal J, Dawson JE, Dyckman E, Hammond PGS, Harris S, et al. Evaluation of indapamide 1.25mg once daily in elderly patients with mild to moderate hypertension. J Hum Hypertens 1997;11:239-44
w50	Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993;22 (Suppl 6):S78-S86
w51	Chalmers JP, Wing LMH, Grygiel JJ, West MJ, Graham JR, Bune AJ. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting. Eur J Clin Pharmacol 1982;22:191-6
w52	Taylor DR, Constable J, Sonnekus M, Milne FJ. Effect of indapamide on serum and red cell cations, with and without magnesium supplementation, in subjects with mild hypertension. S Afr Med J 1988;74:272-6
w53	Weidler D, Jallad NS, Curry C, Ferdinand K, Jain AK, Schnaper HW, et al. Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. J Clin Pharmacol 1995;35:45-51
w54	Ambrosioni E, Safar M, Degaute JP, Malin PL, MacMahon M, Pujol DR, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998;16:1677-84
w55	Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. J Hypertens 2000;18:317-25
w56	Carlsen JE, Køber L, Torp-Pedersen, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990;300:975-8
w57	Christiansen C, Christensen MS, Hagen C, Stocklund KE, Transbøl I. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. Acta Obstet Gynecol Scand 1981;60:407-412
w58	Horvath JS, Caterson RJ, Collett P, Duggin GG, Kelly DH, Tiller DJ. Labetalol and bendrofluazide: comparison of their antihypertensive effects. Med J Aust 1979;1:626-8
w59	Webster J, Dollery CT, Hensby CN. Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension. Clin Sci 1980;59 (Suppl 6):125s-128s
w60	Wilcox RG. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. BMJ 1978;2:383-5
w61	Curry CL, Harris R, MacKay JH, Nugent CA, Ryan J, Schnaper, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension. Clin Ther 1986;9:47-62
w62	Fernandez PG, Zachariah PK, Bryant DG, Missan SS. Antihypertensive efficacy of a -methyldopa, chlorothiazide and Supres-150 (a -methyldopa-chlorothiazide). Can Med Assoc J 1980;123:284-7
w63	McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ 1988;297:95-8
w64	Chrysant SG, Chappel C, Farnham J, Levin B, Lueg M, McCluskey D, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992;32:61-65
w65	Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. J Hypertens 1991;9:1063-8
w66	Verdecchia P, Gatteschi C, Benemio G, Boldrini F, Guerrieri M, Porcellati C. Duration of the antihypertensive action of atenolol, enalapril and placebo. Int J Clin Pharmacol Ther Toxicol 1988;26:570-4
w67	Gostick NK, Mayhew SR, Million R, Sagar D, Suxena SR, Igram DF, et al. A dose-response study of atenolol in mild to moderate hypertension in general practice. Curr Med Res Opin 1977;5:179-84
w68	Cilliers AJ. Atenolol as primary therapy in previously untreated hypertensives and as an adjuvant to other therapy. S Afr Med J 1979;55:321-4
w69	Baez MA, Garg DC, Jallad NS, Weidler DJ. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. Br J Clin Pharmacol 1986;21 (Suppl 1):63S-67S
w70	Maclean D, Mitchell ET, Lewis R, Irvine N, McLay S, McEwen J, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1990;29:455-63
w71	Van Nueten L, Taylor FR, Robertson JIS. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998;12:135-40
w72	Hansson L, Åberg H, Karlberg BE, Westerlund A. Controlled study of atenolol in treatment of hypertension. BMJ 1975;2:367-70
w73	Lange-Andersen KL, Ottmann W, Piatkowski W, Green KA. Working ability and exercise tolerance during treatment of mild hypertension. Int Arch Occup Environ Health 1985;56:49-55
w74	Tonkin AL, Wing LMH, Russell AE, West MJ, Bune AJC, Morris MJ, et al. Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. J Hypertens 1990;8:1015-8
w75	Streufert S, DePadova A, McGlynn T, Pogash R, Piasecki M. Impact of b -blockade on complex cognitive functioning. Am Heart J 1988;116:311-4
w76	Wing LMH, Chalmers JP, West MJ, Russell AE, Morris MJ, Cain MD. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens 1988;10:119-33
w77	Ekbom T, Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Wester P. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 1991;10:1525-9
w78	Saul P, Jones BP, Edwards KG, Tweed JA. Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. Eur J Clin Pharmacol 1985;28:109-110
w79	Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. An assessment of lacidipine and atenolol in mild to moderate hypertension. Br J Clin Pharmacol 1994;37:45-51
w80	Tötterman K, Groop L, Groop P, Kala R, Tolppanen, Fyhrquist F. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. Eur J Clin Pharmacol 1984;26:13-7
w81	Jeffers TA, Webster J, Petrie JC. Atenolol once-daily in hypertension. Br J Clin Pharmacol 1977;4:523-7
w82	Clement DL, Bogaert MG, Pannier R. Effect of beta-adrenergic blockage on blood pressure variation in patients with moderate hypertension. Eur J Clin Pharmacol 1977;11:325-7
w83	Clement DL, De Pue NY, Packet L. Effect of calcium antagonists on ambulatory blood pressure and its variations. J Cardiovasc Pharmacol 1987;10 (Suppl 10):S117-S119
w84	Petrie C, Jeffers TA, Robb OJ, Scott AK, Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. BMJ 1980;1:1573-4
w85	Houston MC, Burger C, Hays JT, Nadeau J, Swift L, Bradley CA, et al. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J 1990;120:172-9
w86	Roberts DH, Tsao Y, MCLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650-3
w87	Wilcox RG, Hampton JR. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. Br Heart J 1981;46:498-502
w88	Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100-4
w89	Broekman CPM, Haensel SM, Ven de Ven LLM, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992;18:325-31
w90	Van de Ven LLM, Mouthaan BJ, Hoes MJ. Treatment of hyperventilation syndrome with bisoprolol: a placebo-controlled clinical trial. J Psychosom Res 1995;39:1007-13
w91	Tseng C, Chiang F, Hsu K, Tseng Y, Hu W, Chen J, et al. Short-term efficacy and safety of bisoprolol in treatment of patients with mild-to-moderate hypertension - A two-center, double-blind study in Taiwan. Acta Cardiologica Sinica 1993;9:155-60
w92	Davidov ME, Singh SP, Vlachakis ND, Blumenthal JB, Simon JS, Bryzinski JS, et al. Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. Clin Cardiol 1994;17:263-268
w93	Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991;68:61-4
w94	Williams RL, Goyle KK, Herman TS, Rofman BA, Ruoff GE, Hogan LB. Dose-dependent effects of betaxolol in hypertension: a double-blind multicenter study. J Clin Pharmacol 1992;32:360-7
w95	Ameling EH, de Korte DF, Man in ’t Veld AJ. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991;18:752-60
w96	Salonen JT, Palminteri R. Comparison of two doses of betaxolol and placebo in hypertension: a randomised, double-blind cross-over trial. Eur J Clin Pharmacol 1982;23:491-4
w97	Gudbjornsdottir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Marin P, et al. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormome levels in hypertensive subjects. Eur J Clin Invest 1997;27;29-35
w98	Groop L, Tötterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. Acta Med Scand 1983;213:9-14
w99	Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994;235:335-41
w100	Jäättelä A, Baandrup S, Houtzagers J, Westergren G. The efficacy of low dose metoprolol CR/ZOK in mild hypertension and in elderly patients with mild to moderate hypertension. J Clin Pharmacol 1990;30 (Suppl):S66-S71
w101	Lepäntalo MJA, Tötterman KJ. Lower limb haemodynamics during antihypertensive treatment with metoprolol and propranolol. Int Angiol 1985;4:225-8
w102	MacMahon S, MacDonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985;1:1233-6
w103	Reybrouck T, Amery A, Fagard R, Jousten P, Lijnen P, Meulepas E. Beta-blockers: once or three times a day? BMJ 1978;1:1386-8
w104	Vandongen R, Margetts B, Deklerk N, Beilin LJ, Rogers P. Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol. Br J Clin Pharmacol 1986;21:627-32
w105	Trafford JAP, Latta D, Little PS, Parsley J, Ankier SI. A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. Curr Med Res Opin 1989;11:550-6
w106	Kimura S, DeQuattro V, Hernandez PH, Lee DD. Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. Am J Cardiol 1988;62:751-4
w107	Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol 1980;9:209-12
w108	Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-44
w109	Himmelmann A, Hedner T, Ssnoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996;51:259-64
w110	van Merode T, van Bortel L M, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989;7 (suppl 6):S262-3
w111	Glassock RJ, Weitzman RE, Bennett CM, Maxwell M, Hamilton B, Winer N, et al. Pindolol: effects on blood pressure and plasma renin activity. Am Heart J 1982;104:421-5
w112	Hamilton BP, Hamilton J, Kirkendall WM. Pulmonary function in hypertensive patients treated with pindolol: a report of two studies. Am Heart J 1982;104:432-7
w113	Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999;45:1170-7
w114	Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol 1998;18:441-6
w115	Pearson RM, Bulpitt CJ, Havard CWH. Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. Lancet 1979;1:697-9
w116	Dargie H, Cleland J, Findlay I, Murray G, McInnes G. Combination of verapamil and beta-blockers in systemic hypertension. Am J Cardiol 1986;57:80D-82D
w117	McInnes GT, Findlay IN, Murray G, Cleland JGF, Dargie HJ. Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens 1985;3 (Suppl 3):S219-21
w118	Galloway DB, Glover SC, Hendry WG, Logie AW, Petrie JC, Smith MC, et al. Propranolol in hypertension: a dose-response study. BMJ 1976;2:140-2
w119	Hudson CFE. An evaluation of once daily long acting propranolol hydrochloride (Inderal LA and Half-Inderal LA) in the treatment of anxiety. A double-blind placebo-controlled general practice study. Br J Clin Pract 1988;42:419-26
w120	Moleur P, Peyrieux JC, Luciani J, David D, Boissel JP. Bopindolol in the treatment of moderate hypertension: a dose-response study. Fundam Clin Pharmacol 1988;2:431-40
w121	Adsett CA, Bellissimo A, Mitchell A, Wilczynski N, Haynes RB. Behavioral and physiological effects of a beta-blocker and relaxation therapy on mild hypertensives. Psychosom Med 1989;51:523-6
w122	Dupont AG, Vanderniepen P, Bossuyt AM, Jonckheer MH, Six RO. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function. Br J Clin Pharmacol 1985;20:93-99
w123	Casadei B, Conway J, Coats AJS, Bird R. Antihypertensive effect of carvedilol: a preliminary dose-response study. Clinical Investigigator 1992;70 (Suppl):S37-S38
w124	Dupont AG, Van der Niepen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt AM, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987;10 (Suppl 11):S130-S136
w125	Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Eng J Med 1998;338:784-90
w126	Chrysant SG, Brown RD, Kem DC, Brown JL. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. Clin Pharmacol Ther 1983;33:741-6
w127	Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1987;23:652-7
w128	Küppers HE, Jäger BA, Luszick JH, Gräve, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997;15:93-7
w129	Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. Clin Pharmacol Ther 1991;50:96-106
w130	Forette F, Handfield-Jones R, Henry-Amar M, Fouchard M, Bouchacourt P, Hervy M, et al. Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril. Gerontology 1987;33:9-16
w131	van Baak MA, Mooij JMV, Wijnen JAG, Tan FS. Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension. Clin Pharmacol Ther 1991;50:221-7
w132	Bergstrand R, Herlitz H, Johansson S, Berglund G, Vedin A, Wilhelmsson C, et al. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol 1985;19:605-11
w133	Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton G, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 1989;62:112-7
w134	Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. Am J Hypertens 1989;2:352-4
w135	Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997;79:431-5
w136	Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, Smith LK. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998;11:23-30
w137	Whelton A, Dunne B, Glazer N, Kostis JB, Miller WE, Rector DJ, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992;6:325-31
w138	Levine JH, Ferdinand KC, Cargo P, Laine H, Lefkowitz M. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995;8:494-9
w139	Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-51
w140	Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50
w141	Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6
w142	Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46
w143	Smith DHG, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-90
w144	Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997;11 (Suppl 2):S61-62
w145	Simon G, Morioka S, Snyder DK, Cohn JN. Increased renal plasma flow in long-term enalapril treatment of hypertension. Clin Pharmacol Ther 1983;34:459-65
w146	Sassano P, Chatellier G, Alhenc-Gelas F, Corvol P, Menard J. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. Am J Med 1984;77(suppl 2A):18-22
w147	Bilan A, Chibowska M, Palusinski R, Witczak, Ostrowski S, Makaruk B, et al. Enalapril (10 mg/day) in systemic sclerosis. Adv Exp Med Biol 1999;455:285-8
w148	Applegate WB, Cohen JD, Wolfson P, Davis A, Green S. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Am J Cardiol 1996;78:51-5
w149	Gerritsen TA, Bak AAA, Stolk RP, Jonker JJC, Grobbee DE. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. J Hypertens 1998;16:689-96
w150	Morgan TO, Morgan O, Anderson A. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. Clin Exp Pharmacol Physiol 1995;22:778-80
w151	Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FIR. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998;47 (suppl 1):12-15
w152	Luccioni R, Frances Y, Gass R, Gilgenkrantz JM. Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension. Clin Exp Hypertens 1989;A11:521-34
w153	West JNW, Smith SA, Stallard TJ, Littler WA. Effects of perindopril on ambulatory intra-arterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension. J Hypertens 1989;7:97-104
w154	Louis WJ, Workman BS, Conway EL, Worland P, Rowley K, Drummer O, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol 1992;20:505-11
w155	Chrysant SG, McDonald RH, Wright JT, Barden PL, Weiss RJ. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. Clin Pharmacol Ther 1993;53:479-84
w156	Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24h after dosing. Am J Cardiol 1996;12:1191-6
w157	Overlack A, Adamczak M, Bachmann W, Bönner G, Bretzel RG, Derichs R, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. Am J Med 1994;97:126-34
w158	Cheung R, Lewanczuk RZ, Rodger NW, Huff MW, Oddou-Stock P, Botteri F, et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract 1999;53:584-92
w159	Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, Rossetti M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens 1987;5 (Suppl 4):S139-S142
w160	Schoenberger JA, Wilson DJ. Once-daily treatment of essential hypertension with captopril. J Clin Hypertens 1986;4:379-87
w161	Conway J, Way B, Boon N, Somers V. Is the antihypertensive effect of captopril influenced by the dosage frequency? A study with ambulatory monitoring. J Hum Hypertens 1988;2:123-6
w162	Lavessaro G, Ladetto PE, Valente M, Stramignoni D, Zanna C, Assogna G, et al. Ketanserin and captopril interaction in the treatment of essential hypertensives. Cardiovasc Drugs Ther 1990;4:119-22
w163	Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984;144:1947-53
w164	Salvetti A, Circo A, Raciti S, Gulizia M, Cardillo R, Miceli S, et al. Captopril at 50mg as well as at 100mg once a day reduces blood pressure for up to 24h: a double-blind randomized crossover study in mild to moderate hypertensives. J Hypertens 1988;6 (Suppl 4):S666-S668
w165	Wiggam MI, Hunter SJ, Atkinson AB, Ennis CN, Henry JS, Browne JN, et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens 1998;16:1651-7
w166	Drayer JIM, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983;5 (Suppl III):III108-13
w167	Insua A, Ribstein J, Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgrad Med J 1988;64 (Suppl 3):59-62
w168	Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension 1995;26:124-30
w169	Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-81
w170	DeQuattro V, Lee D. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997;10 (Suppl):138S-145S
w171	Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. Am J Hypertens 1997;10:492-9
w172	De Bruijn JHB, Orofiamma BA, Pauly NC. Efficacy and tolerance of trandolapril (0.5-2mg) administered for 4 weeks in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994;23 (Suppl 4):S60-S64
w173	Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998;11:322-7
w174	Pritchard G, Lyons D, Webster J, Petrie JC, MacDonald TM. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Br J Clin Pharmacol 1997;44:145-9
w175	Kohlmann O , Jardim PCBV, Oigman W. Brazilian multicenter on efficacy and tolerability in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. Arq Bras Cardiol 1999;72:553-7
w176	Mancia G, De Cesaris R, Fogari R, Lattuada S, Montemurro G, Palombo C, et al. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure. Am J Cardiol 1992;70:60D-66D
w177	Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. Br J Clin Pharmacol 1998;45:491-5
w178	Mroczek WJ, Klein J, Burris JF. Dose-finding study of cilazapril (inhibace) in patients with uncomplicated essential hypertension. Clin Exp Hypertens 1991;A13:1415-32
w179	Prager G, Klein P, Schmitt M, Prager R. Antihypertensive efficacy of cilazapril 2.5 and 5.0mg once-daily versus placebo on office blood pressure and 24-hour blood pressure profile. J Cardiovasc Pharmacol 1994;24 (Suppl 3):S93-S99
w180	Kobrin I, Güntzel P, Viskoper R, Paran E, Zimlichman R. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension. Drugs 1991;41:31-6
w181	Güntzel P, Kobrin I, Pasquier C, Zimlichman R, Viskoper JR. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients. J Cardiovasc Pharmacol 1991;17:8-12
w182	Lacourcière Y, Leenen F, Rangno R, Spence JD, Lenis JH, Myers MG. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy. Can J Cardiol 1994;10:605-10
w183	Fernandez PG, Bolli P, Lee C. The 24h blood pressure responses of hypertensives to a once-a-day cilazapril regimen. Can J Cardiol 1990;6:53-8
w184	Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. J Cardiovasc Pharmacol 1992;20:451-7
w185	White WB, McCabe EJ, Hager WD, Schulman P. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise and ambulatory blood pressure. Clin Pharmacol Ther 1988;44 (Suppl 3):173-8
w186	Poirier L, Pyzyk M, Provencher P, Lacourciére. Comparative effects of 2.5 and 5mg cilazapril versus placebo on daily blood pressure load. Am J Hypertens 1991;4:913-5
w187	Burris JF. The effect of ramipril on ambulatory blood pressure: a multicenter study. J Cardiovasc Pharmacol 1991;18 (Suppl 2):S131-3
w188	McCarron D. 24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Clin Cardiol 1991;14:737-42
w189	Schnaper HW. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1991;18 (Suppl 2):S128-S130
w190	Homuth V, Faulhaber H, Loose U, Löffler K, Luft FC. Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial. Am J Cardiol 1993;72:666-71
w191	Villamil AS, Cairns V, Witte PU, Bertolasi CA. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo. Am J Cardiol 1987;59:110D-114D
w192	Kahan T, Eliasson K. The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension. Am J Hypertens 1999;12:1188-94
w193	Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. Clin Exp Hypertens 1999;21:1447-62
w194	Chan P, Lin C, Tomlinson B, Lin T, Lee Y. Additive effects of diltiazem and lisinopril in treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997;10:743-9
w195	Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9
w196	Thürig C, Böhlen L, Schneider M, de Courten M, Shaw SG, Riesen W, et al. Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur J Clin Pharmacol 1995;49:21-6
w197	Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, et al. Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 1995;9:541-6
w198	Tomei R, Rossi L, Carbonieri E, Franceschini L, Molon G, Zardini P. Antihypertensive effect of lisinopril assessed by 24-hour ambulatory monitoring: a double-blind, placebo-controlled, cross-over study. J Cardiovasc Pharmacol 1992;19:911-14
w199	Polónia J, Martins L, Macedo F, Faria DB, Simões, Brandão F, et al. Lisinopril and diltiazem reduce left ventricular mass without changing blood pressure in normotensive subjects with exaggerated blood pressure response to exercise. Rev Port Cardiol 1996;15:185-93
w200	Gomez JH, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 1989;28:415-20
w201	Cuspidi C, Lonati L, Sampieri L, Leonetti G, Muiesan ML, Agabiti-Rosei E, et al. Lack of effect of short-term lisinopril administration on left ventricular filling dynamics in hypertensive patients with diastolic dysfunction. Blood Pressure 1997;6:307-12
w202	Lee AFC, Dick JBC, Bonnar CE, Struthers AD. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci 1999;96:441-8
w203	Maclean D. Quinapril: a double-blind, placebo-controlled trial in essential hypertension. Angiology 1989;40:370-81
w204	Säynävälammi P, Pörsti I, Pörsti P, Nurmi A, Seppälä E, Manninen V, et al. Effects of the converting enzyme inhibitor quinapril on blood pressure, renin-angiotensin system and prostanoids in essential hypertension. J Cardiovasc Pharmacol 1988;12:88-93
w205	Gupta RK, Kjeldsen SE, Motley E, Weder AB, Sweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991;17:13-9
w206	Kjeldsen SE, Gupta RK, Krause L, Weder AB, Julius S. Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril. Am Heart J 1992;123:1433-8
w207	Kontopoulos AG, Athyros VG,Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-361
w208	Ford NF, Fulmor IE, Nichola PS, Alpin PG, Herron JM. Fosinopril monotherapy: relationship between blood pressure reduction and time of administration. Clin Cardiol 1993;16:324-30
w209	Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991;17:636-42
w210	Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther 1990;12:520-33
w211	Guitard C, Lohmann FW, Alfiero R, Ruina M, Alvisi V. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. Cardiovasc Drugs Ther 1997;11:449-57
w212	Guitard C, Sasssano P, Tzincoca C, Duchiez J, Safar ME. Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension. Blood Press 1994;3 (suppl 2):61-8
w213	Guitard C, Alvisi V, Maibach E, Franck J, Cocco G, Boxho G, et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. Blood Press 1994;3 (suppl 2):81-7
w214	Fairhurst GJ. A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. Blood Press 1994;3 (suppl 2):77-80
w215	Frishman WH, Ram CVS, McMahon FG, Chrysant SG, Graff A, Kupiec JW, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol 1995;35:1060-6
w216	Kuschnir E, Acuña E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 10 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213-24
w217	Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. J Human Hypertens 1999;13:337-42
w218	Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hum Hypertens 2000;13:1045-8
w219	Christensen PK, Lund S, Parving H-H. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 2001;60:1435-42
w220	Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11:S55-6
w221	Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. Eur J Clin Pharmacol 1997;53:221-8
w222	Elmfeldt D, George M, Hűbner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin-II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997;11:S49-53
w223	Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001;21:17-23
w224	Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999;12:1181-7
w225	Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin-II antagonist, in comparison with losartan. Blood Press 1998;7:53-9
w226	Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998;82:961-5
w227	Bell TP, DeQuattro V, Lasseter KC, Ruff D, Hardison JD, Cushing D, et al. Effective dose range of candesartan cilexetil for systemic hypertension. Am J Cardiol 1999;83:272-5
w228	Zuschke CA, Keys I, Munger MA, Carr AA, Marinides GN, Flanagan TL, et al. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Clin Ther 1999;21:464-74
w229	Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, et al. A comparison of angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414-7
w230	Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810
w231	Neutel J, Weber M, Pool J, Smigh D, Fitzsimmons S, Chiang Y-T, et al. Valsartan, a new angiotensin-II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997;19:447-58
w232	Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-15
w233	Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin-II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53
w234	Mallion M, Siche JP, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin-II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-64
w235	Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualsiero P, Varricchio G, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997;11:307-12
w236	Fagard R, Lijnen P, Pardaens K, Thijs L, Vinck W. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. J Hum Hypertens 2001;15:161-7
w237	Cheetham C, O’Driscoll G, Standon K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci 2001;100:13-7
w238	Pancera P, Persciuttini B, Sansone S, Montagna L, Paluani F, Covi G, et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. J Hypertens 1999;17:513-21
w239	Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995;13:S29-33
w240	Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50mg and losartan 50mg titrated to 100mg in patients with essential hypertension. Blood Press 1997;6:35-43
w241	Pűchler K, Laeis P Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin-II antagonist. J Hypertens 2001;19:S41-8
w242	Pool JL, Glazer R, Chiang Y-T, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin-II receptor blocker. J Hum Hypertens 1999;13:275-81
w243	Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and tolerability of irbesartan, an angiotensin-II receptor antagonist, in primary hypertension. Clin Drug Invest 1998;3:217-27
w244	Fogari R, Ambrosoli S, Corradi L, Esposti ED, Mos L, Nami R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hum Hypertens 1997;15:1511-8
w245	Pool JL, Guthrie RM, Littlejohn TW, Raskin P, Shephard AMM, Weber A, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70
w246	Benetos A, Gautier S, Laflèche A, Topouchian Jm Frangin G, Girerd X, et al. Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res 2000;37:8-15
w247	McGill JB, Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomised double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833-50
w248	Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Therapy 1998;15:206-17
w249	Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M. Efficacy and tolerability of tasosartan, a novel angiotensin-II receptor blocker: results from a 10-week, double-blind, placebo controlled, dose-titration study. Am Heart J 1999;137:118-25
w250	Feldman R, Chattman MS, Lonigro A, Sievers RJ. Tasosartan in patients with essential hypertension: a randomized, double-blind, dose-titration study. Adv Therapy 1997;14:290-303
w251	Rhéaume C, Waib PH, Lacourcière Y, Cléroux J. Effects of angiotensing antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. J Hypertens 1998;16:2085-9
w252	Lacourcière Y, Pool JL, Svetkey L, Gradman AH, Larochelle P, de Champlain J, et al. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Am J Hypertens 1998;11:454-61
w253	Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin-II antagonist, in patients with systemic hypertension. Clin Ther 1999;21:442-53
w254	Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens 1999;17:129-36
w255	White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens 2001;14:1248-55
w256	Schmitz A, Pedersen MM, Mogensen CE. Effects of felodipine on urinary albumin excretion and metabolic control in hypertensive non-insulin-dependent diabetics. Am J Hypertens 1990;3:611-617
w257	Campbell LM, Cowen KJ, Cranfield FR, Goves JR, Jones DF, Lees CTW, et al. Felodipine-ER once daily as monotherapy in hypertension. J Cardiovasc Pharmacol 1990;15:569-573
w258	Cooperative Study Group. Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Drugs 1987;34(Suppl 3):139-148
w259	Crozier IG, Ikram H, Nicholls MG, Low CJS. Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension. Cardiovasc Drugs Ther 1990;4:439-442
w260	Fagan TC. Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. J Am Geriatr Soc 1997;45:712-717
w261	Hamilton DV, Barnes PC, Bowles RML, Rajaratnam DV, Comerford MB, Ginks WR, et al. Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension. J Cardiovasc Pharmacol 1987;10(supplS):S111-S113
w262	Hosie J, Mulder AW, Westberg B. Felodipine once daily in elderly hypertensives. J Hum Hypertens 1991;5:49-53
w263	Liedholm H, Melander A. A placebo-controlled dose-response study of felodipine extended release in hypertensive patients. J Cardiovasc Pharmacol 1989;14:109-113
w264	Madsen JK, Zachariae H, Pedersen EB. Effects of the calcium antagonist felodipine on renal aerodynamics, tubular sodium handling, and blood pressure in cyclosporin-treated dermatological patients. Nephrol Dial Transplant 1997;12:480-484
w265	McGrath BP, Watts RW, Elmfeldt DB. Clinical equivalence of two tablet formulations of felodipine. Eur J Clin Pharmacol 1995;49:169-172
w266	Pannarale G, Puddu PE, Monti F, Irace L, Bentivoglio M, Collauto F, et al. Twenty-four antihypertensive efficacy of felodipine 10 mg extended-release: the Italian inter-university study. J Cardiovasc Pharmacol 1996;27:255-261
w267	Porcellati C, Verdecchia P, Gatteschi C, Benemio G, Guerrieri M, Boldrini F, et al. Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. Eur J Clin Pharmacol 1989;37:555-557
w268	Bonaduce D, Canonico V, Petretta M, Forgione L, Ianniciello A, Cavallaro V, et al. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study. Eur J Clin Pharmacol;1997;53:95-100
w269	van Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. J Hum Hypertens 1996;10:613-618
w270	Weber MA, Goldberg AI, Faisons EP, Lipschutz K, Shapiro DA, Nelson EB, et al. Extended-release felodipine in patients with mild to moderate hypertension. Clin Pharmacol Ther 1994;55:346-352
w271	Wester A, Lorimer AR, Westberg B. Felodipine extended release in mild to moderate hypertension. Curr Med Res Opin 1991;12:275-281
w272	Bossini A, Di Veroli C, Cavallotti G, Cagli V. Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo. Br J Clin Pharmac 1990;30:567-571
w273	Andersson OK, Persson B, Hedner T, Aurell M, Wysocki M. Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men. J Hypertens 1989;7:465-469
w274	Arosio E, Pancera P, Priante F, Ribul M, De Marchi S, Lechi A. Effects of sustained-release isradipine on blood pressure and peripheral hemodynamics in hypertensive patients. Clin Ther 1993;15:705-713
w275	Arzilli E, Gandolfi E, Del Prato C, Innocenti P, Ponzanelli F, Gaiazza A, et al. Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study. Eur J Clin Pharmacol 1993;44:23-25
w276	Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. J Clin Pharmacol 1995;35:239-243
w277	Cléroux J, Yardley C, Marshall A, Coulombe D, Lacourcière Y. Antihypertensive and hemodynamic effects of calcium channel blockade with isradipine after acute exercise. Am J Hypertens 1992;5:84-87
w278	Fogari R, Malacco E, Tettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring. Br J Clin Pharmacol 1993;35:51-54
w279	Holmes DG, Isradipine: a slow-release formulation given once daily controls blood pressure for 24h. Am J Hypertens 1993;6:74S-76S
w280	The Italian-Belgian Isradipine Study Group. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. Am J Med 1989;86:94-97
w281	Kirch W, Burger KJ, Weidinger G, Welzel D. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. J Cardiovasc Pharmacol 1990;15(Suppl 1):S55-S59
w282	Low CJS, Foy SG, Chaudhary H, Crozier IG, Baskaranathan S, Ikram H. Twenty-four hour profile of the anti-hypertensive action of isradipine in essential hypertension. Blood Pressure 1993;2:59-61
w283	Nelson EB, Pool JL, Taylor AA. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. Clin Pharmacol Ther 1986;40:694-7
w284	O’Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H. Effect of isradipine on in-vivo platelet function. Thromb Res 1997;86:363-371
w285	Rab SM, Mirza MA, Khan MH, Samad A, Ahmed M. Double-blind multicentre isradipine dose-confirmation study in Pakistan. Drugs 1990;40(Suppl 2):30-32
w286	Simonsen K. Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. Am J Med 1989;86:91-93
w287	Staessen J, Lijnen P, Fagard R, Hespel P, Tan WP, Devos P, et al. Effects of the new calcium entry blocker isradipine (NP 200-110) in essential hypertension. J Cardiovascular Pharmacol 1989;13:271-276
w288	Bremner AD, Fell PJ, Hosie J, James IGV, Saul PA, Taylor SH. Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. J Hum Hypertens 1993;7:79-81
w289	Carr AA, Bottini PB, Prisant LM, Mulligan S, Devane JG, Fisher L, et al. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992;69(SupplE):28E-32E
w290	Corbin DOC, Wood DA, Macintyre CCA, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud’s phenomenon. Eur Heart J 1986;7:165-170
w291	Eggertsen R, Hansson L. Effects of treatment with nifedipine and metoprolol in essential hypertension. Eur J Clin Pharmacol 1982;21:389-390
w292	Feig PU, Gibson L, MacCarthy EP, Pettis PP, Schwartz L. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Clin Ther 1993;15:963-975
w293	Handa K, Mori T, Tanaka H, Takada Y, Matsunagga A, Kiyonaga A, et al. Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects. Cardiovasc Drugs Ther 1992;6:85-90
w294	Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. Drugs 1994;48:23-31
w295	Landmark K, Dale J. Antihypertensive, haemodynamic and metabolic effects of nifedipine slow-release tablets in elderly patients. Acta Medica Scandinavica 1985;218:389-396
w296	Ozenne G, Moore ND, Leprevost A, Tardif C, Boismare F, Pasquis P, et al.Nifedipine in chronic bronchial asthma: a randomised double-blind crossover trial against placebo. Eur J Resp Dis 1985;67:238-243
w297	Patakas D, Maniki E, Tsāra V, Dascalōpōulou E. Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol 1987;79:959-963
w298	Salvetti A, Virdis A, Taddei S, Ambrosoli S, Caiazza A, Gandolfi E, et al. Trough:peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study. J Hypertens 1996;14:661-667
w299	Sand J, Nordback I, Koskinen M, Matikainen M, Lindholm TS. Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol 1993;4:530-535
w300	De Simone G, Ferrara LA, Fasano ML, Di Lorenzo L, Lauria R. Slow-release nifedipine versus placebo in the treatment of arterial hypertension. Jpn Heart J 1985;26:219-225
w301	Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension. Can J Cardiol 1997;13:921-927
w302	Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained release formulation of nifedipine. J Clin Pharmacol 1990;30:1012-1019
w303	Harder S, Rietbrock S, Thűrmann P. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. Drug Res 1994;44:133-136
w304	Licata G, Scaglione R, Ganguzza A, Parrinello G, Costa R, Merlino G, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. Eur J Clin Pharmacol 1993;45:307-311
w305	Lorimer AR, Smedsrud T, Walker P, Tyler HM. A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. J Hum Hypertens 1989;3:191-196
w306	Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. Am J Cardiol 1990;66:1269-1271
w307	Mehta JL, Lopez LM, Vlachakis ND, Gradman AH, Nash DT, O’Connell MT, et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J 1993;125:1704-1709
w308	Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988;12(Suppl 7):S79-84
w309	Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC, Towler HM. Once daily amlodipine in the treatment of mild to moderate hypertension. Br J Clin Pharmacol 1987;24:713-719
w310	Frick MH, McGibney D, Tyler HM. Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension. J Cardiovasc Pharmacol 1988;12(Suppl 7):S76-S78
w311	Ahmed JH, Elliott HL, Hosie J, Rafish E, Reid JL. Effects of nicardipine on the metabolic responses to food and exercise. J Hum Hypertens 1992;6:139-144
w312	Bellett M, Pagny J-Y, Chatellier G, Corvol P, Ménard J. Evaluation of slow release nicardipine in essential hypertension by casual and ambulatory blood pressure measurements. Effects of acute versus chronic administration. J Hypertens 1987;5:599-604
w313	Cox JP, Ryan J, O’Brien E, O’Malley K. The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension. Br J Clin Pharmacol 1989;28:79-82
w314	Fagan TC, Tyler ED, Reitman MA, Kenley S, Weber MA. Sustained-release nicardipine in mild-to-moderate hypertension. Chest 1993;104:427-433
w315	Mazzola C, Borgnino C, Colombo D, Lissoni F, Serra G, Turri DR, et al. Antihypertensive and hemodynamic effects of slow-release nicardipine. Int J Clin Pharmacol Ther Toxicol 1988;26:503-508
w316	Salvetti A, Cardellino G, Pesenti M, Caiazza A, Ghisoni F, Del Prato C, et al. Antihypertensive effect of slow-release nicardipine. A placebo-controlled cross-over study. Eur J Clin Pharmacol 1989;36:439-442
w317	Soro S, Cocca A, Pasanisi F, Tommaselli A, de Simone G, Costantino G, et al. The effects of nicardipine on sodium and calcium metabolism in hypertensive patients: a chronic study. J Clin Pharmacol 1990;30:133-137
w318	Webster J, Petrie JC, Jeffers TA, Roy-Chaudhury P, Crichton W, Witte K, et al. Nicardipine sustained release in hypertension. Br J Clin Pharmacol 1991;32:433-439
w319	Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831-1838
w320	Opie LH, Műller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YK, et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. Am J Hypertens 1997;10:250-260
w321	Lijnen P, Petrov V. Blood pressure and cationic transport systems during combined calcium channel blocker and calcium administration in males. Methods Find Exp Clin Pharmacol 1996;18:287-294
w322	Morris AD, Donnelly R, Connell JMC, Reid JL. Effects of the calcium antagonist lacidipine on insulin sensitivity in essential hypertension. Horm Metab Res 1994;26:257-259
w323	Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. J Cardiovasc Pharmacol 1991;17(Suppl 4):S39-S44
w324	Ueda S, Donnelly R, Panfilov V, Morris AD, Elliott HL. Lacidipine: effects on vascular pressure responses throughout the dosage interval in normotensive subjects. Br J Clin Pharmacol 1998;46:127-132
w325	Lacourcière Y, Poirier L, Lefebvre J, Burford RG. Clinical efficacy of force titrated doses of diltiazem extended-release. Am J Hypertens 1995;8:282-286
w326	Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, et al. A dose-response trial of once-daily diltiazem. Am Heart J 1992;123:1022-1026
w327	Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCL, in mature and elderly hypertensive patients. Clin Ther 1994;16:209-221
w328	Dupont AG, Coupez JM, Jensen P, Coupez-Lopinot R, Schoors DF, Hermanns P, et al. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension. Cardiovasc Drugs Ther 1991;5:701-708
w329	Meeves SG, Park GD. The use of confidence intervals to describe the precision of trough/peak ratios for diltiazem CD in the treatment of hypertension. J Clin Pharmacol 1994;34:231-235
w330	Meeves S, Hafner K, Park G, Weber M. Three-period crossover trial with ambulatory blood pressure monitoring for evaluating antihypertensive therapy. Am Heart J 1995;130:841-848
w331	Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985;56(supplH):86H-91H
w332	Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo controlled study with 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992;32:808-815
w333	Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992;14:148-157
w334	Van Merode T, Van Bortel L, Smeets FAM, Bőhm R, Mooij J, Rahn KH, et al. The effects of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. J Cardiovasc Pharmacol 1990;15:109-113
w335	Hedbäck B, Hermann LS. Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension. Acta Medica Scandinavica Suppl 1984;681:129-35
w336	Kimose H-H, Bagger JP, Aagaard MT, Paulsen PK. Placebo-controlled, double-blind study of the effect of verapamil in intermittent claudication. Angiology1990;41:595-598
w337	Carr AA, Bottini PB, Prisant LM, Fisher LD, Devane JG, O’Brien DE, Rhoades RB. Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. J Clin Pharmacol 1991;31:144-150
w338	McMahon FG, Reder RF. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. J Clin Pharmacol 1989;29:1003-1007
w339	Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J 1996;132:1202-1206
w340	Corea L, Bentivoglio M, Berioli S, Bianchini C, Savino K, Sardina M. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind placebo-controlled study with 24-hour ambulatory blood pressure monitoring. Cardiovascular Drugs Therapy 1990;4:1501-1508
w341	Lewis GRJ, Morley KD, Lewis BM, Bones PJ. The treatment of hypertension with verapamil. NZ Med J 1978;87:351-354
w342	Van Bortel LMAB, Schiffers PMH, Bőhm ROB, Mooij JMV, Rahn KH, Struyker Boudier HAJ. The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients. Eur J Clin Pharmacol 1990;39(Suppl 1):S39-S40
w343	White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995;76:375-380

 

 

Web table A Average changes (95% confidence intervals) in persons taking thiazides, according to dose, in serum concentrations of total cholesterol and its low (LDL), high (HDL) and very low (VLDL) density lipoprotein subfractions, potassium, glucose, uric acid, adjusted for changes in the placebo groups, in randomised trials of thiazides

Web table A Average changes (95% confidence intervals) in persons taking thiazides, according to dose, in serum concentrations of total cholesterol and its low (LDL), high (HDL) and very low (VLDL) density lipoprotein subfractions, potassium, glucose, uric acid, adjusted for changes in the placebo groups, in randomised trials of thiazides

Dose of thiazide:

Half-standard dose

Standard dose

Twice-standard dose

No of trials*

Average change (mmol/l)

change as % of mean

Average change (mmol/l)

change as % of mean

Average change (mmol/l)

change as % of mean

Cholesterol:

13

total

0.06 (-0.04 to 0.17)†

1%

0.18 (0.10 to 0.27)

3%

0.30 (0.14 to 0.47)

5%

LDL

-0.09 (-0.28 to 0.11)†

-2%

-0.04 (-0.02 to 0.13)†

-1%

0.01 (-0.23 to 0.26)†

1%

HDL

-0.03 (-0.08 to 0.03)†

-2%

-0.004 (-0.01 to 0.02)†

0%

0.03 (-0.01 to 0.08)†

3%

VLDL

0.07 (-0.09 to 0.23)†

12%

0.13 (0.03 to 0.23)

22%

0.19 (0.09 to 0.29)

32%

Potassium

27

-0.21 (-0.28 to -0.14)

-6%

-0.38 (-0.44 to -0.33)

-9%

-0.55 (-0.64 to -0.46)

-13%

Glucose

15

0.06 (0.00 to 0.12)

1%

0.19 (0.10 to 0.27)

3%

0.31 (0.18 to 0.45)

5%

Uric acid

20

0.032 (0.027 to 0.037)

9%

0.048 (0.043 to 0.053)

15%

0.064 (0.054 to 0.074)

21%

† Not statistically significant; however upper confidence interval is informative

* Reference numbers:

Cholesterol fractions: w2,w22,w28,w31,w33,w36,w44,w47-50,w56,w57

Potassium: w4,w25-41,w47-52,w56,w61,w63.

Glucose: w2,w28,w31-38,w47-50,w56

Uric acid: w9,w29-40,w47-51,w56,w63

Online poll

Find out more>>